Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

bausch health ireland limited - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orion corporation - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

tillomed pharma gmbh - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - fingolimodhydrochlorid - kapsler, hårde - 0,25 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pensa pharma ab - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

reddy holding gmbh - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multipel sclerose - selektive immunosuppressiva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

neuraxpharm sweden ab - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg